Bambusa Therapeutics (BBTX) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bambusa Therapeutics is the larger company by market cap ($815.1 million vs $779.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBTX | MGTX |
|---|---|---|
| Share price | $16.00 | $7.98 |
| Market cap | $815.08M | $779.89M |
| 1-day change | +2.89% | -1.97% |
| YTD return | — | +0.38% |
| 1-year return | — | +6.97% |
| 5-year return | — | -55.54% |
| P/E ratio (TTM) | — | 9.17 |
| EPS (TTM) | $-1.73 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $81.39M |
| Revenue growth (YoY) | — | +144.57% |
| Net income (latest FY) | — | $-114.20M |
| Operating margin | — | -130.20% |
| Net margin | — | -140.31% |
| 52-week high | $17.65 | $15.35 |
| 52-week low | $13.60 | $6.62 |
| Distance from 52-week high | -9.35% | -48.01% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +247.74% |
| Average volume | 359.41K | 837.25K |
| Shares outstanding | 50.94M | 97.73M |
| Employees | 26 | 386 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bambusa Therapeutics
BBTX stock →Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 386 employees
BBTX vs MGTX FAQ
Which is bigger, Bambusa Therapeutics or MeiraGTx?
Bambusa Therapeutics (BBTX) is larger, with a market capitalization of $815.08M compared with $779.89M for MeiraGTx (MGTX).
Are Bambusa Therapeutics and MeiraGTx in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.